Rein Therapeutics, Inc.

RNTX

Rein Therapeutics, Inc.

RNTX

Insider Sentiment (TTM):

Last Purchase:2026-05-27Last Sale:2024-06-17Shares Purchased (TTM):312,075Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:11,366,042Shares Outstanding:30,354,647Institutional Ownership Pct.:37.44%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	9	4	3	4	6	7	13	18	22	12	17	12
Prepaid Expense And Other Assets Current	1	1	1	1	1	1	1	1	1	1	1	1
Restricted Cash Current	-	-	-	-	-	-	-	0	0	0	0	0
Assets Current	41	5	4	5	7	8	14	19	23	13	18	13
Property Plant And Equipment Net	-	-	0	0	0	0	0	0	0	0	0	0
Goodwill	6	6	6	6	6	6	6	6	6	6	6	-
Intangible Assets Net Excluding Goodwill	14	14	14	42	42	42	42	79	79	79	79	-
Other Assets Noncurrent	2	1	0	0	2	1	0	0	1	1	2	-
Assets	66	26	24	54	57	58	62	104	109	99	106	13
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	6	4	4	6	1	1	1	1	2	1	0
Accrued Liabilities And Other Liabilities	2	2	2	2	2	5	5	5	4	2	3	1
Operating Lease Liability Current	-	-	-	-	-	-	-	-	-	-	0	-
Notes Payable Current	-	5	-	-	-	-	-	-	-	-	-	-
Liabilities Current	10	14	6	6	8	6	6	6	5	5	4	2
Deferred Income Tax Liabilities Net	1	1	1	2	2	2	2	3	3	3	3	-
Other Liabilities Noncurrent	-	-	0	0	0	0	0	-	0	-	-	-
Liabilities	11	15	7	8	9	8	8	9	8	8	8	2
Temporary Equity Carrying Amount Attributable To P…	45	45	45	45	45	45	45	45	45	47	91	-
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Subscriptions	-	-	-	-	0	-	-	-	-	-	-	-
Additional Paid In Capital Common Stock	424	374	373	370	367	362	361	361	361	340	295	292
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-
Retained Earnings Accumulated Deficit	-413	-407	-401	-369	-364	-357	-351	-310	-305	-296	-289	-281
Liabilities And Stockholders Equity	66	26	24	54	57	58	62	104	109	99	106	13
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	-	-	0.001
Preferred Stock Shares Authorized	-	-	-	-	-	-	-	-	-	-	-	5
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	-	-	-	0
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	0
Stockholders Equity	-	-	-	-	-	-	-	-	-	-	7	11
Temporary Equity Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-
Temporary Equity Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	-
Temporary Equity Shares Issued	0	0	0	0	0	0	0	0	0	0	0	-
Temporary Equity Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	45	45
Common Stock Shares Issued	86	28	28	25	23	22	22	22	22	17	5	5
Shares Outstanding	86	28	28	25	23	22	22	22	22	17	5	5

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-10.19%	-5.52%	-29.81%	-	-	-	-	-	-	-	-	-
2025	-15.25%	-36.02%	-52.97%	15.15%	3.03%	35.50%	8.80%	0.00%	4.00%	38.58%	-17.32%	-24.57%
2024	-16.92%	-26.41%	-47.44%	51.35%	91.89%	116.22%	-33.53%	-31.12%	-40.48%	10.98%	18.90%	-10.37%
2023	-	-	-	-	-	-	-7.27%	97.44%	143.73%	-35.58%	-45.36%	-51.60%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.27	0.40	0.70	0.90	0.86	1.39	2.38	3.30	4.69	2.82	4.17	7.88
Quick Ratio	4.19	0.33	0.52	0.70	0.74	1.24	2.24	3.12	4.44	2.66	3.96	7.45
Working Capital	31.74M	-8.18M	-1.85M	-570.00K	-1.09M	2.35M	7.91M	13.03M	18.22M	8.23M	13.88M	11.17M
Leverage & Debt
Debt to Equity	0.20	1.27	0.43	0.16	0.20	0.16	0.14	0.09	0.08	0.09	0.08	0.15
Interest Coverage TTM	-	-	-	-	-	-	-	-	-164.63	-69.18	-50.55	-42.51
Debt Ratio	0.16	0.56	0.30	0.14	0.16	0.13	0.13	0.09	0.08	0.08	0.07	0.13
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.74	-1.65	-1.96	-2.23	-2.45	-2.80	-3.51	-1.35	-1.27	-2.18	-3.42	-2.85
Free Cash Flow Per Share TTM	-0.28	-0.55	-0.76	-0.79	-0.88	-1.06	-1.24	-1.29	-1.29	-2.46	-4.31	-3.04
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-15.87%	-18.06%	-20.69%	101.38%	134.53%	239.15%	299.71%	125.97%	44.28%	-23.73%	-42.43%	-56.26%
EPS Growth (1Y)	-69.67%	-40.84%	-44.09%	65.49%	93.07%	28.47%	2.47%	-52.63%	-67.10%	-58.28%	-43.18%	-56.26%
Valuation Metrics
P/E TTM	-1.40	-0.79	-0.59	-0.51	-0.57	-0.63	-0.66	-2.62	-2.19	-3.05	-0.89	-0.53
P/B TTM	1.26	3.40	1.74	0.65	0.71	0.78	0.76	0.81	0.55	0.60	0.14	0.62
Market Cap	69.77M	39.46M	29.52M	30.18M	33.86M	38.79M	41.26M	76.69M	55.15M	55.04M	14.02M	6.90M
Enterprise Value	61.23M	39.94M	26.30M	26.14M	28.14M	31.36M	28.39M	59.04M	33.24M	43.00M	-3.29M	-5.17M
Calculated Values
Free Cash Flow TTM	-18.83M	-16.61M	-19.36M	-20.95M	-21.22M	-23.20M	-22.29M	-27.87M	-25.69M	-20.42M	-19.81M	-13.83M
Net Debt	-8.54M	478.00K	-3.22M	-4.05M	-5.72M	-7.43M	-12.87M	-17.65M	-21.92M	-12.04M	-17.31M	-12.07M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-27Purchase

Owner: Von, Rickenbach Josef H

Title: -

Shares: 4,500

Price/Share: $1.07

Value: $4,815.00

Shares Owned: 62,514

Relationship: Director

Ownership: Direct

2026-04-30Purchase

Owner: Windsor, James Brian

Title: See Remarks

Shares: 25,000

Price/Share: $1.00

Value: $25,000.00

Shares Owned: 27,046

Relationship: Director,Officer

Ownership: Direct

2025-11-14Purchase

Owner: Voss, Value Master Fund, …

Title: -

Shares: 104,183

Price/Share: $1.22

Value: $127,103.26

Shares Owned: 926,441

Relationship: TenPercentOwner

Ownership: Indirect

2025-10-28Purchase

Owner: Voss, Value-Oriented Spec…

Title: -

Shares: 178,392

Price/Share: $1.39

Value: $247,964.88

Shares Owned: 500,000

Relationship: TenPercentOwner

Ownership: Indirect

2024-12-05Purchase

Owner: Windsor, James Brian

Title: President and CEO

Shares: 400

Price/Share: $2.24

Value: $896.00

Shares Owned: 239

Relationship: Officer

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-27	Von, Rickenbach Josef H	Director	-	Direct	Purchase	4,500	1.07	$4,815.00	62,514	4
2026-04-30	Windsor, James Brian	Director,Officer	See Remarks	Direct	Purchase	25,000	1.00	$25,000.00	27,046	4
2025-11-14	Voss, Value Master Fund, …	TenPercentOwner	-	Indirect	Purchase	104,183	1.22	$127,103.26	926,441	4
2025-10-28	Voss, Value-Oriented Spec…	TenPercentOwner	-	Indirect	Purchase	178,392	1.39	$247,964.88	500,000	4
2024-12-05	Windsor, James Brian	Officer	President and CEO	Indirect	Purchase	400	2.24	$896.00	239	4
2024-06-17	University, Of Texas/Texa…	TenPercentOwner	-	Direct	Sale	4,707	3.25	$15,297.75	1,746,549	4
2024-06-12	University, Of Texas/Texa…	TenPercentOwner	-	Direct	Sale	9,342	3.26	$30,454.92	1,753,156	4
2024-06-07	University, Of Texas/Texa…	TenPercentOwner	-	Direct	Sale	1,740	3.28	$5,707.20	1,777,827	4
2024-05-01	University, Of Texas/Texa…	TenPercentOwner	-	Direct	Sale	20,315	4.22	$85,729.30	1,790,142	4/A
2024-04-30	University, Of Texas/Texa…	TenPercentOwner	-	Direct	Sale	90	4.97	$447.30	1,799,621	4
2023-12-15	Windsor, James Brian	Officer	President and COO	Indirect	Purchase	225	3.37	$758.25	225	4
2023-11-20	Windsor, James Brian	Officer	President and COO	Direct	Purchase	5,076	1.97	$9,999.72	5,122	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

37.44%

Inst. Shares: 11,366,042

Shares Outstanding: 30,354,647

2025-12-31

42.29%

Inst. Shares: 10,761,349

Shares Outstanding: 25,444,795

2025-09-30

27.53%

Inst. Shares: 7,256,388

Shares Outstanding: 26,361,386

2025-06-30

27.52%

Inst. Shares: 6,657,209

Shares Outstanding: 24,187,536

2025-03-31

27.35%

Inst. Shares: 5,995,080

Shares Outstanding: 21,915,891

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	11,366,042	30,354,647	37.44%
2025-12-31	10,761,349	25,444,795	42.29%
2025-09-30	7,256,388	26,361,386	27.53%
2025-06-30	6,657,209	24,187,536	27.52%
2025-03-31	5,995,080	21,915,891	27.35%
2024-12-31	5,679,222	17,938,899	31.66%
2024-09-30	4,605,051	21,663,089	21.26%
2024-06-30	3,012,726	19,911,462	15.13%
2024-03-31	1,643,431	8,301,798	19.80%
2023-12-31	1,035,544	4,598,715	22.52%
2023-09-30	1,026,566	4,541,167	22.61%
2023-06-30	1,006,840	4,541,167	22.17%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Rein Therapeutics, Inc. (RNTX) — SEC Financial Statements & Analysis

Rein Therapeutics, Inc. (RNTX) is a pharmaceutical preparations company. Rein Therapeutics, Inc. trades on Nasdaq as: RNTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Rein Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.20x, a Price-to-Book (P/B) ratio of 1.26x (TTM), at a market cap of $69.77M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.20x
P/B TTM: 1.26x
Market Cap: $69.77M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Rein Therapeutics, Inc. in?

Rein Therapeutics, Inc. (RNTX) operates in the Pharmaceutical Preparations industry.

What is RNTX's market cap?

Rein Therapeutics, Inc. (RNTX) has a market capitalization of $69.77M as of 2026-06-30.

What exchange does RNTX trade on?

Rein Therapeutics, Inc. (RNTX) trades on the Nasdaq.